MarketPR
The number moving the tape for Virax Biolabs Group Limited (Nasdaq: VRAX) is $3.3 million, the gross proceeds from a definitive agreement the London-based company entered July 9, 2026.
The deal covers the immediate exercise of certain outstanding preferred investment options. The next confirmable milestone is the formal filing from Virax Biolabs detailing the full transaction terms.
The transaction The preferred investment options were outstanding before the July 9 announcement, meaning the instruments predated this agreement.
Virax Biolabs entered the definitive agreement for their immediate exercise. Gross proceeds of $3.3 million flow to the company on completion.
Keep reading